Rnd3 Protects Against Doxorubicin-Induced Heart Damage
Author Information
Author(s): Ge Wen, Zhang Xiaohua, Lin Jie, Wang Yangyang, Zhang Xiao, Duan Yu, Dai Xinchun, Zhang Jiye, Zhang Yan, Jiang Mengyuan, Qiang Huanhuan, Zhao Zhijing, Zhang Xuebin, Sun Dongdong
Primary Institution: Department of Cardiology, Xijing Hospital, Fourth Military Medical University, Xi’an, Shaanxi China
Hypothesis
Rnd3 may serve as a critical pathogenic factor in doxorubicin-induced cardiotoxicity (DIC).
Conclusion
Rnd3 enhances cardiac resilience against doxorubicin-induced cardiotoxicity by stabilizing mitochondrial dynamics and reducing PANoptosis.
Supporting Evidence
- Rnd3 expression is significantly downregulated in doxorubicin-treated mice.
- Rnd3 overexpression improves cardiac function and reduces cardiac enzyme levels in doxorubicin-treated mice.
- Rnd3 inhibits mitochondrial fission by reducing Drp1 phosphorylation.
- Rnd3 reduces PANoptosis in cardiomyocytes exposed to doxorubicin.
Takeaway
This study shows that a protein called Rnd3 helps protect the heart from damage caused by a cancer drug called doxorubicin by keeping the tiny powerhouses in cells, called mitochondria, healthy.
Methodology
The study used cardiomyocyte-specific Rnd3 transgenic mice and in vitro experiments with adenoviruses to assess the effects of Rnd3 on doxorubicin-induced cardiotoxicity.
Participant Demographics
Male mice were used in the experiments.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website